CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Quince Therapeuticks Inc - QNCX CFD

1.8182
8.55%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0836
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024318 %
Charges from full value of position ($-4.62)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024318%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002096 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002096%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.9882
Open 1.9582
1-Year Change 101.86%
Day's Range 1.8182 - 1.9582
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 4, 2024 1.9882 -0.0700 -3.40% 2.0582 2.1082 1.9582
Dec 3, 2024 2.1282 0.0400 1.92% 2.0882 2.1782 1.9982
Dec 2, 2024 2.0482 0.0700 3.54% 1.9782 2.1182 1.9282
Nov 29, 2024 1.9982 -0.0300 -1.48% 2.0282 2.0482 1.9582
Nov 27, 2024 2.0182 0.0200 1.00% 1.9982 2.0882 1.9782
Nov 26, 2024 1.9782 -0.0500 -2.47% 2.0282 2.0482 1.9782
Nov 25, 2024 1.9582 -0.0400 -2.00% 1.9982 2.1182 1.9282
Nov 22, 2024 1.9182 -0.2500 -11.53% 2.1682 2.4382 1.6482
Nov 21, 2024 2.0482 0.2600 14.54% 1.7882 2.1182 1.7582
Nov 20, 2024 1.8282 0.0600 3.39% 1.7682 1.8282 1.7382
Nov 19, 2024 1.7682 0.0500 2.91% 1.7182 1.7782 1.6982
Nov 18, 2024 1.7282 -0.0400 -2.26% 1.7682 1.7782 1.6982
Nov 15, 2024 1.7382 -0.1800 -9.38% 1.9182 2.0682 1.5882
Nov 14, 2024 1.8682 0.2600 16.17% 1.6082 1.9282 1.6082
Nov 13, 2024 1.5982 -0.0200 -1.24% 1.6182 1.6882 1.5482
Nov 12, 2024 1.6382 0.0600 3.80% 1.5782 1.6982 1.5182
Nov 11, 2024 1.6482 -0.0300 -1.79% 1.6782 1.6882 1.5982
Nov 8, 2024 1.6482 0.1500 10.01% 1.4982 1.6982 1.4982
Nov 7, 2024 1.5282 -0.0300 -1.93% 1.5582 1.6382 1.4882
Nov 6, 2024 1.4282 0.0100 0.71% 1.4182 1.4582 1.3882

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cortexyme Inc. Company profile

About Cortexyme Inc

Cortexyme, Inc. is a clinical stage biopharmaceutical company that is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company provides 3CLpro inhibitor, COR803 product, is a lead compound for treatment of coronavirus infections. The Company’s products pipeline includes drug candidates for the treatment of central nervous system (CNS) disorders including Alzheimer’s disease; for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of underserved and chronic conditions such as periodontitis. The Company’s COR388 is for the treatment of Alzheimer’s disease and Parkinson's disease. The Company's COR588 is in Phase I clinical trial and targeting to use in the treatment of periodontal disease and other P. gingivalis-related indications. The Company is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cortexyme Inc revenues was not reported. Net loss increased 17% to $89.9M. Higher net loss reflects Stock-based Compensation in R&D increase from $7M to $15.1M (expense), Stock-based Compensation in GA increase of 99% to $14.8M (expense), General and administrative - Balancing increase of 45% to $14.7M (expense).

Industry: Biotechnology & Medical Research (NEC)

601 Gateway Boulevard, Suite 1250
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

People also watch

BTC/USD

101,872.15 Price
+4.520% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,634.13 Price
-0.530% 1D Chg, %
Long position overnight fee -0.0170%
Short position overnight fee 0.0088%
Overnight fee time 22:00 (UTC)
Spread 0.30

Oil - Crude

68.50 Price
+0.180% 1D Chg, %
Long position overnight fee 0.0087%
Short position overnight fee -0.0306%
Overnight fee time 22:00 (UTC)
Spread 0.030

ETH/USD

3,887.33 Price
+1.130% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading